+

WO1997001338A1 - Inhibiteurs de la thrombine a base de pyridinone - Google Patents

Inhibiteurs de la thrombine a base de pyridinone Download PDF

Info

Publication number
WO1997001338A1
WO1997001338A1 PCT/US1996/010778 US9610778W WO9701338A1 WO 1997001338 A1 WO1997001338 A1 WO 1997001338A1 US 9610778 W US9610778 W US 9610778W WO 9701338 A1 WO9701338 A1 WO 9701338A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyridinone
mmol
compound
amino
Prior art date
Application number
PCT/US1996/010778
Other languages
English (en)
Inventor
Philip E. Sanderson
Adel M. Naylor-Olsen
Dona L. Dyer
Joseph P. Vacca
Richard C. A. Isaacs
Bruce D. Dorsey
Mark E. Fraley
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603450.9A external-priority patent/GB9603450D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU63917/96A priority Critical patent/AU703744B2/en
Priority to EP96923399A priority patent/EP0835109A4/fr
Priority to JP9504499A priority patent/JPH11508558A/ja
Publication of WO1997001338A1 publication Critical patent/WO1997001338A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Definitions

  • Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.
  • European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.
  • Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or a-keto carboxyl derivatives.
  • the invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
  • compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
  • the compositions can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.
  • the invention also includes a composition for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
  • These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
  • the invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.
  • Compounds of the invention are useful as thrombin inhibitors and have therapeutic value in for example, preventing coronary artery disease, and have the following structure:
  • n 0-4, m is 1 or 2, and q is 0 or 1 , with the proviso that where n is 1 -4, q is 1 and m is 1 , and where n is 0, m is 1 or 2, and q is 0 or 1 , and where n is 0, m is 2 and q is 0, R 1 can be the same or different;
  • R 2 O(CH 2 ) p , wherein p is 1-4; R 2 is
  • phenyl unsubstituted or substituted with one or more of C 1 - 4 linear or branched alkyl, C 1 -4 linear or branched alkoxy, halogen, trifluoromethyl, hydroxy, COOH, or CONH 2 ,
  • a 5- to 7- membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,
  • A is chosen from one of the following Radicals:
  • R 4 and R 5 are independently H, C 1 -4 linear or branched alkyl or alkoxy; C 3 -C 7 cycloalkyl; halogen; or trifluoromethyl;
  • a useful class of compounds is the embodiment wherein W is R 1 or R 1 SO 2 .
  • a further useful subclass of compounds is the embodiment wherein R 1 is R 2 (CH 2 ) n , (R 2 ) 2 CH(CH 2 ) n , phenyl, or (phenyl) 2 -CH.
  • R 3 is C 1 -4 linear or branched alkyl and particularly wherein R 3 is methyl.
  • R 4 is C 1 -4 linear or branched alkyl and R 5 is methyl or hydrogen and particularly wherein R 4 is methyl and R 5 is methyl or hydrogen and most particularly when R 4 is methyl and R 5 is hydrogen.
  • W is R 1 SO 2 and A is Radical II (in which both configurations of the trans radical are contemplated within the scope of this invention).
  • A is Radical II (in which both configurations of the trans radical are contemplated within the scope of this invention).
  • Specific embodiments of this class include (note that the methyl group is conventionally indicated as a single bond attached to a ring):
  • W is R 1 SO 2 and A is Radical III.
  • Specific embodiments of this class include:
  • W is R 1 SO 2 and A is Radical IV.
  • Specific embodiments of this class include:
  • the compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.
  • a racemate or racemic mixture does not imply a 50:50 mixture of stereoisomers.
  • alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy” represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "Halo”, as used herein, means fluoro, chloro, bromo and iodo; and
  • counterion is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.
  • C 3 -7cycloalkyl is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.
  • C 7- 12 bicyclic alkyl is intended to include bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1 ,1,3-trimethyl-bicyclo[2.2.1]heptyl (bornyl), and the like.
  • heterocycle or "heterocyclic ring”, as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur
  • heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • rings containing one oxygen or sulfur, one to three nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms are especially useful.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl,
  • Morpholino is the same as morpholinyl.
  • Formula I in the form of water- or oil-soluble or dispersible products
  • the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
  • acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate,
  • glycerophosphate hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate.
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • Thrombin inhibitors - therapeutic uses and methods of using
  • Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy.
  • patient used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.
  • Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage.
  • the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems
  • the thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.
  • the thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient.
  • the active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants.
  • Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.
  • the thrombin inhibitors can also be administered in the form of Hposome delivery systems, such as small unilamellar vesicles, large uni lamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinlypyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • the dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
  • Oral dosages of the thrombin inhibitors when used for the indicated effects, will range between about 0.1 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably 1.0-100 mg/kg/day and most preferably 1 -20 mg/kg/day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
  • the thrombin inhibitors may be administered in divided doses of two, three, or four times daily.
  • they can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.
  • thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier” materials) suitably selected with respect to the intended form of
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders, lubricants, distintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.
  • thrombin inhibitors can also be co-administered with suitable anti-coagulation agents or thrombolytic agents such as
  • thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion.
  • Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be combined with heparin, aspirin, or warfarin.
  • Methods A to E can be used to prepare the compounds of the present invention.
  • Two methods for preparing compounds which contain radical IV as an end group are illustrated as Methods A and B and are exemplified by Examples I and XXV.
  • methyl-2-hydroxy-6-methylpyridinone-3-carboxylate is alkylated with t-butylbromoacetate using a base such as cesium carbonate in DMF, or sodium hydride in THF.
  • the t-butyl group is removed using a strong acid such as HCl gas and the amide of 4-aminomethyl-1-t-butoxycarbonylpiperidine is made using a standard coupling procedure.
  • the methyl ester is hydrolyzed with lithium hydroxide and then a Curtius rearrangement (with acyl azide formation using DPPA and triethylamine as the base) gives the
  • amidinopiperidine formation can be performed using an amidine transfer reagent such as aminoiminomethanesulfonic acid with triethylamine as a base in DMF.
  • an amidine transfer reagent such as aminoiminomethanesulfonic acid with triethylamine as a base in DMF.
  • One of the sulfonyl groups is then removed using aqueous lithium hydroxide.
  • Amide couplings e.g., Step D in Method A, to form the compounds of this invention can be performed by the carbodiimide method with reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide.
  • reagents such as dicyclohexylcarbodiimide, or 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide.
  • Other methods of forming the amide or peptide bond include, but are not limited to the synthetic routes via an acid chloride, azide, mixed anhydride or activated ester.
  • solution phase amide couplings are performed, but solid-phase synthesis by classical Merrifield techniques may be employed instead.
  • the addition and removal of one or more protecting groups is also typical practice.
  • Methods A to E will allow different W, A and R 3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step.
  • the starting pyridine in Step A can have as the 6-substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 .
  • different W groups can be present by the use of an appropriate alkylating, carbonylating,
  • Step H Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 , R 1 OCO, R 1 CO, R 1 SO 2 , or
  • Step A starting 6-methyl-2-hydroxy-pyridine carboxylic acid is reacted with diphenylphosphoryl azide (DPPA) and benzyl alcohol in Step A to afford the protected pyridinone.
  • DPPA diphenylphosphoryl azide
  • Step B benzyl alcohol
  • This is alkylated with a glycine equivalent in Step B such as t-butylbromoacetate using a base such as cesium carbonate or sodium hydride.
  • the t-butyl group is removed using a strong acid such as HCl gas in Step C and the amide of 4-aminomethyl-1-t-butoxycarbonylpiperidine is made using a standard coupling procedure in Step D.
  • the CBZ group is removed in Step E via hydrogenation over a catalyst.
  • the resulting amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step F with pyridine as an acid scavenger and the BOC group is then removed in Step G using a strong acid such as HCl gas.
  • Amidinopiperidine formation can be performed using an amidine transfer reagent such as aminoiminomethanesulfonic acid with triethylamine as a base in DMF.
  • the product of step G can be reacted with cyanogen bromide to give the cyanamide in Step H which can be further reacted with hydroxylamine to give the hydroxyguanidine.
  • Method B Modifications of Method B will allow different W, A and R 3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step.
  • the starting pyridine in Step A can have as the 6-substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 .
  • different W groups can be present by the use of an appropriate alkylating, carbonylating,
  • Step F Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide,
  • alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 , R 1 OCO, R 1 CO, R 1 SO 2 , or
  • hydroxide and the amide of trans -4-t-butoxycarbonylaminocyclohexylmethylamine is made using a standard coupling procedure.
  • the nitro group is reduced by hydrogenation using a palladium catalyst under standard conditions.
  • the amino group is alkylated by reduction with sodium triacetoxyborohydride of the imine formed from phenylacetaldehyde.
  • the BOC group is removed using a strong acid such as HCl gas.
  • Method C Modifications of Method C will allow different W, A and R3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step.
  • the starting pyridine in Step A can have as the 6-substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R3.
  • different W groups can be present by the use of an appropriate alkylating, carbonylating,
  • Step E Use of, for example, an alkyl aldehyde, alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the following alkyl aldehyde, alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate.
  • Step A the CBZ group is removed from the product of Method B, Step B via hydrogenation over a catalyst.
  • the resulting amine is then reacted with the appropriate reagent, in this case benzylsulfonyl chloride, in Step B with pyridine as an acid scavenger and the t-butyl ester is then removed under acidic conditions in Step C.
  • the acid is then coupled in Step D with an amine, such as 2-t-butoxycarbonylamino-6-methyl-5-aminomethyl pyridine and the BOC group is removed in Step E with a strong acid.
  • Method D Modifications of Method D will allow different W, A and R 3 groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step.
  • the starting pyridinone in Step A can have as the 6-substituent, ethyl, isopropyl, cyclopropyl, and the like, to achieve the different operable values of R 3 .
  • different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealyting agent, and the like, in Step B.
  • Use of, for example, an alkyl halide, alkoxycarbonyl halide, acyl halide, alkylsulfonyl halide, or alkyl isocyanate will yield the
  • METHOD E For preparing compounds which contain a 6-trifluoromethylpyridinone, one can use the following illustrated Method E. As exemplified by Example XXIII, starting butyl-2-trifluoroacetylvinyl ether is condensed with nitroacetamide in the presence of a base such as sodium ethoxide in Step A. The resulting pyridinone is allylated using ⁇ -allyl palladium in Step B and the nitro- group is reduced in Step C. The amine is then reacted with the following illustrated Method E. As exemplified by Example XXIII, starting butyl-2-trifluoroacetylvinyl ether is condensed with nitroacetamide in the presence of a base such as sodium ethoxide in Step A. The resulting pyridinone is allylated using ⁇ -allyl palladium in Step B and the nitro- group is reduced in Step C. The amine is then reacted with the
  • Step D with pyridine as an acid scavenger.
  • olefin is oxidatively cleaved to give the aldehyde which is further oxidised to the acid in Step E.
  • the acid is then coupled in Step F with an amine, such as 2-t-butoxycarbonylamino-6-methyl-5-aminomethyl pyridine and the BOC group is removed with a strong acid.
  • Method E Modifications of Method E will allow different W and A groups contemplated by the scope of the broad claim below to be present by the use of an appropriate reagent or appropriately substituted starting material in the indicated synthetic step.
  • different W groups can be present by the use of an appropriate alkylating, carbonylating, sulfonylating, urealyting agent, and the like, in Step E.
  • alkylsulfonyl halide, or alkyl isocyanate will yield the corresponding values of W where W is R 1 , R 1 OCO, R 1 CO, R 1 SO 2 , or
  • NMR field strength employed in the below given examples was either 300 or 400 MHz.
  • Step D Methyl-6-methyl-1-(4-methylenecarboxamidomethyl-1- t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxylate
  • EDC hydrochloride (2.34 g, 12.18 mmol) was added to a stirred mixture of methyl-6-methyl-1-methylenecarboxy-2-pyridinone-3-carboxylate (2.0 g, 8.88 mmol), 4-aminomethyl-1-t-butoxycarbonyl-piperidine (3.0 g, 14.21 mmol), HOBT (1.65 g, 12.18 mmol) and diisopropylethylamine (3.6 ml, 10.30 mmol) in dry DMF (20 ml).
  • Step E 6-Methyl-1-(4-methylenecarboxamidomethyl-1-t- butoxy-carbonylpiperidinyl)-2-pyridinone-3-carboxylic acid
  • Lithium hydroxide (8.23 ml of 1 M aqueous solution) was added to a stirred solution of methyl-6-methyl-1-(4-methylenecarbox- amidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxy late (2.31 g, 5.48 mmol) in 1 : 1 methanol/THF (16 ml).
  • Step F 3-Benzyloxycarbonylamino-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2- pyridinone
  • DPPA (1.53 ml, 7.11 mmol) was added to a stirred solution of 6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone-3-carboxylic acid (1.93 g, 4.74 mmol) and triethylamine (0.99 ml, 7.11 mmol) in dry dioxane (10 ml) and the resulting solution was heated to reflux. After 48 h more triethylamine (0.99 ml, 7.11 mmol) and benzyl alcohol (0.74 ml, 7.11 mmol) were added and the solution was refluxed for a further 24 h.
  • Step G 3-Amino-6-methyl-1-(4-methylenecarboxamidomethyl-1 - t-butoxycarbonylpiperidinyl)-2-pyridinone
  • Step H 3-N,N-(Bis-benzylsulfonyl)amino-6-methyl-1-(4- methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone
  • Benzylsulfonyl chloride (51 mg, 0.27 mmol) was added to a stirred solution of 3-amino-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone (68 mg, 0.18 mmol) and triethylamine (0.075 ml, 0.54 mmol) in dry methylene chloride (0.5 ml).
  • Step I 3-Benzylsulfonylamino-6-methyl-1-(4-methylenecarboxamidomethyl-1-amidinopiperidinyl)-2-pyridinone HCl Gas was bubbled through a solution of 3-N,N-(Bis-benzylsulfonyl)amino-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone (30 mg, 0.044 mmol) in 1 : 1 methylene chloride/ethyl acetate (2 ml) for 5 min at 0°C. After a further 1 h the solution was degassed with argon and was evaporated in vacuo to a glass.
  • Step C 3-Nitro-6-methyl-1-(methylenecarboxamido-trans-4-t- butoxycarbonylaminocyclohexylmethyl)--2-pyridinone
  • EDC hydrochloride (249 mg, 1.30 mmol) was added to a stirred mixture of 3-nitro-6-methyl-1-methylenecarboxy-2-pyridinone (212 mg, 1.00 mmol), trans-4-t-butoxycarbonylaminocyclohexylmethylamine (228 mg, 1.00 mmol), HOBT (176 mg, 1.30 mmol) and
  • Step D 3- Amino-6-methyl-1-(methylenecarboxamido-trans-4- t-butoxycarbonylaminocyclohexylmethyl)-2-pyridinone
  • Step E 3-(2-Phenylethylamino)-6-methyl-1-(methylenecarboxamido-trans-4-t-butoxycarbonylaminocyclohexylmethyl)-2-pyridinone
  • Step F 3-(2-Phenylethylamino)-6-methyl-1-(methylenecarboxamido-trans-4-aminocyclohexylmethyl)-2-pyridinone
  • Step A 3-Benzylsulfonylamino-6-methyl-1 - (methylenecarboxamido-trans-4-t-butyloxycarbonylamino-cyclohexylmethyl)-2-pyridinone
  • EDC hydrochloride 50 mg, 0.260 mmol was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (73 mg, 0.217 mmol), trans-4-t-butoxycarbonylaminocyclohexylmethylamine (51 mg, 0.260 mmol), HOBT (35 mg, 0.260 mmol) and triethylamine (0.073 ml, 0.521 mmol) in dry DMF (3 ml).
  • Step B 3-Benzylsulfonylamino-6-methyl-1 -(methylenecarboxamido-trans-4-aminocyclohexylmethyl)-2-pyridinone
  • Step C 3-Amino-6-methyl-1-(t-butyl-methylenecarboxy)-2- pyridinone
  • Step D 3-Benzylsulfonylamino-6-methyl-1 -(t-butyl-methylenecarboxy)-2-pyridinone
  • the cloudy ethyl acetate layer was dried (Na 2 SO 4 ) and was evaporated in vacuo to give the desired product (1.42 g) as a pale pink solid. More product (0.97 g as a pale yellow solid) was recovered by washing the drying agent and filtration apparatus with methylene chloride.
  • Step E 3-Benzylsulfonylamino-6-methyl-1 -methylenecarboxy-2- pyridinone
  • HCl gas was bubbled through a stirred suspension of 3-benzylsulfonylamino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (1.42 g, 3.62 mmol) in ethyl acetate (15 ml) at 0°C until a solution had formed which was saturated with HCl. After 1 h at RT a thick suspension had formed. The mixture was degassed with argon and filtered to give the title compound (0.865 g, 71 %) as a solid:
  • Step F 3-Benzylsulfonylamino-6-methyl-l -(2-amino-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • EDC hydrochloride (34.2 mg, 0.178 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (50.0 mg, 0.149 mmol), 2-amino-4-methylaminopyridine (18.3 mg, 0.149 mmol), HOBT (24.1 mg, 0.178 mmol) and triethylamine (0.050 ml, 0.359 mmol) in dry DMF (1 ml). After 64 h the reaction was diluted with ethyl acetate and was washed with water, saturated sodium hydrogen carbonate solution, water and brine, dried (Na 2 SO 4 ) and evaporated in vacuo to a solid.
  • DPPA (35.6 ml, 165 mmol) was added to a stirred solution of 2-hydroxy-6-methylpyridine-3-carboxylic acid (22.97 g, 165 mmol) and triethylamine (23.0 ml, 165 mmol) in dry dioxane (300 ml) and the resulting solution was heated to reflux. After 16 h more triethylamine (23.0 ml, 165 mmol) and benzyl alcohol (17.1 ml, 150 mmol) were added and the solution was refluxed for a further 24 h. The reaction was concentrated in vacuo to remove most of the volatiles.
  • Step C 3-Amino-6-methyl-1-(t-butyl-methylenecarboxy)-2- pyridinone
  • Step D 3-Benzylsulfonylamino-6-methyl-1 -(t-butyl-methylenecarboxy)-2-pyridinone
  • Benzylsulfonyl chloride (3.146 g, 16.5 mmol) was added to a solution of 3-amino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (3.55 g, 14.9 mmol) in pyridine (30 ml) at 0° C and as the resulting solution was stirred a thick precipitate formed. After 1 h the reaction mixture was evaporated in vacuo to a thick paste. This was partitioned between methylene chloride and 10% potassium hydrogen sulfate solution.
  • HCl gas was bubbled through a stirred suspension of 3-benzylsulfony lamino-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (5.70 g, 14.52 mmol) in ethyl acetate (60 ml) at 0°C until a solution had formed which was saturated with HCl. After 1.5 h at RT a thick suspension had formed.
  • Step F 3-Benzylsulfonylamino-6-methyl-1 -(2-amino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone DCC (0.61 g, 2.98 mmol) was added to a stirred solution of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone ( 1.00 g, 2.98 mmol) and 2-t-butoxycarbonylamino-6-methyl-5-methylaminopyridine (0.71 g, 2.98 mmol) in methylene chloride (6 ml). After 3 h the reaction was filtered through celite and evaporated in vacuo to a pale yellow foam.
  • Step C 3-Nitro-1-(2-t-butoxycarbonylamino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • EDC hydrochloride (249 mg, 1.30 mmol) was added to a stirred mixture of 3-nitro-1-methylenecarboxy-2-pyridinone (198 mg, 1.00 mmol), 2-t-butoxycarbonylamino-5-methylamino-6-methylpyridine (237 mg, 1.00 mmol), HOBT (176 mg, 1.30 mmol) and triethylamine (0.32 ml, 2.30 mmol) in dry DMF (4 ml). After 16 h the solvent was evaporated in vacuo, and the residue was partitioned between methylene chloride and water. The organic layer was dried (Na 2 SO 4 ) and
  • Step D 3- Amino-1-(2-t-butoxycarbonylamino-6-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Step E 3-Benzylsulfonylamino-1-(2-t-butoxycarbonylamino-6- methyl-5-methylenecarboxamidomethylpyridinyl)-2- pyridinone
  • Step F 3-Benzylsulfonylamino-1-(2-amino-6-methyl-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Step C 3-Benzylsulfonylamino-6-methyl-1 -(2-amino-3-methyl- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • EDC hydrochloride (69 mg, 0.36 mmol) was added to a stirred mixture of 3-benzylsulfonylamino-6-methyl-1-methylenecarboxy-2-pyridinone (101 mg, 0.30 mmol), 2-amino-5-methylamino-3-methylpyridine (63 mg, 0.30 mmol), HOBT (49 mg, 0.36 mmol) and triethylamine (0.22 ml) in dry DMF (1.2 ml). After 64 h the reaction was evaporated in vacuo then was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium hydrogen carbonate solution and brine, dried (Na 2 SO 4 ) and evaporated in vacuo to a glass. The crude product was purified by preparative HPLC (C 18 ,
  • HCl gas was bubbled through a stirred suspension of 3-benzloxycarbonylamino-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone (0.12 g) in ethyl acetate (5 ml) at 0° C until a solution had formed which was saturated with HCl.
  • Step A 3-(3-Phenylpropionamido)-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2- pyridinone
  • Hydrocinnamoyl chloride 56 mg, 0.329 mmol was added to a stirred solution of 3-amino-6-methyl-1-(4-methylene-carboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone (83 mg, 0.220 mmol) and triethylamine (92 ⁇ l, 0.660 mmol) in methylene chloride (1 ml).
  • Step B 3-(3-Phenylpropionamido)-6-methyl-1-(4-methylenecarboxamidomethyl-1-amidinopiperidinyl)-2-pyridinone 3-(3-Phenylpropionamido)-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone
  • Step A 3-(3,3-Diphenylpropionamido)-6-methyl-1-(4-methylenecarboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2- pyridinone
  • EDC hydrochloride 75 mg, 0.393 mmol was added to a stirred mixture of 3-amino-6-methyl-1-(4-methylene-carboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone (99 mg, 0.262 mmol), 3,3-diphenylpropionic acid (71 mg, 0.314 mmol), HOBT (53 mg, 0.393 mmol) and diisopropylethylamine (0.14 ml, 0.786 mmol) in dry DMF (1 ml). After 64 h the reaction was diluted with ethyl acetate and was washed with water, dried (MgSO 4 ) and evaporated in vacuo.
  • Step B 3-(3,3-Diphenylpropionamido)-6-methyl-1-(4-methylenecarboxamidomethyl-1-amidinopiperidinyl)-2-pyridinone 3-(3,3-Diphenylpropionamido)-6-methyl-1-(4-methylene ⁇ carboxamidomethyl-1-t-butoxycarbonylpiperidinyl)-2-pyridinone
  • Step A 3-p-Toluenesulfonylamino-6-methyl-1-(4- methylenecarboxamidomethyl-1-t- butoxycarbonylpiperidinyl)-2-pyridinone
  • Step A 3-p-Toluenesulfonylamino-6-methyl-1-(methylene- carboxamido-trans-4-t-butoxycarbonylaminocyclo- hexylmethyl)-2-pyridinone
  • Step B 3-p-Toluenesulfonylamino-6-methyl-1-(methylenecarboxamido-trans-4-aminocyclohexylmethyl)-2-pyridinone
  • Step A 3-Phenylacetamido-6-methyl-1-(2-t-butoxycarbonylamino- 5-methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Phenylacetyl chloride (18 mg, 0.1 14 mmol) was added to a stirred solution of 3-amino-6-methyl-1-(2-t-butoxycarbonylamino-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (40 mg, 0.103 mmol) in pyridine ( 1 ml). After 1 h the reaction mixture was partitioned between methylene chloride and water. The organic layer was washed with water and brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
  • Step B Phenylacetamido-6-methyl-1-(2-amino-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • the title compund was prepared from 1-napthylsulfonyl chloride (64 mg, 0.283 mmol) and 3-amino-6-methyl-1-(2-t-butoxycarbonylamino-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (0.100 g, 0.258 mmol) using the procedure of EXAMPLE XIII, as a white solid, m.p.
  • Step B 3-(4-Trifluoromethylbenzylsulfonyl)amino-6-methyl- 1-(2-t-butoxycarbonylamino-6-methyl-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • the title compound was prepared from 3-amino-6-methyl-1-(2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamido-methylpyridinyl)-2-pyridinone (0.100 g, 0.249 mmol) and 4-trifluoromethylbenzylsulfonyl chloride (64 mg, 0.249 mmol) using the procedure of EXAMPLE XIII, as a white solid (60 mg), m.p.
  • the title compound was prepared from 3-amino-6-methyl-1-(2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (0.100 g, 0.249 mmol) and 2-napthylsulfonyl chloride (56 mg, 0.249 mmol) using the procedure of EXAMPLE Xffl, as a white solid (72 mg), m.p. >200°C: 1 H NMR
  • Step A The title compound was prepared from 4-fluoromethylbenzyl chloride (1.0 g) using the procedure of EXAMPLE XVI, Step A, as a heavy oil.
  • Step B The title compound was prepared from 3-amino-6-methyl-1-(2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (0.100 g, 0.249 mmol) and 4-fluoromethylbenzylsulfonyl chloride (52 mg, 0.246 mmol) using the procedure of EXAMPLE XIII, as a white solid: 1 H NMR (CD 3 OD) ⁇ 2.33 (s, 3 H),
  • the title compound was prepared from 3-amino-6-methyl-1- (2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethyl pyridinyl)-2-pyridinone (0.060 g, 0.15 mmol) and phenylacetaldehyde (19.5 ⁇ l, 0.165 mmol) using the procedure of EXAMPLE III, as a pale yellow solid, m.p.
  • Step A 3-(4-Chloro-benzylsulfonylamino)-6-methyl-1-(t-butyl- methylenecarboxy)-2-pyridinone
  • Step B 3-(4-Chloro-benzylsulfonylamino)-6-methyl-1-(2-amino-6- methyl-5-methylenecarboxamidomethylpyridinyl)-2- pyridinone
  • HCl gas was bubbled through a stirred suspension of 3-(4-chloro-benzylsulfonylamino)-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone (325 mg, 14.52 mmol) in ethyl acetate (10 ml) at 0°C until a solution had formed which was saturated with HCl. After 1.5 h a thick suspension had formed. The mixture was degassed with argon and filtered to give the title compound (202 mg) as a solid, m.p. >200°C: 1 H NMR (DMSO) see disappearance of the BOC group; HRMS (FAB) calc'd for C 22 H 25 N 5 O 4 SCI (M+1) + 490.1316, found 490.1300.
  • the reaction was heated to reflux for 64 h, and more allyl acetate (13.5 ml, 125 mmol), triphenylphosphine (525 mg, 2.0 mmol), palladium acetate (122 mg, 0.5 mmol), and tetrahydrofuran (13 ml) were added. After a further 24 h and 48 h at reflux addditional allyl acetate (13.5 ml, 125 mmol), palladium acetate (122 mg, 0.5 mmol), and triphenylphosphine (525 mg, 2.0 mmol) were added and the reaction was heated to reflux for a further 24 h.
  • reaction was cooled and evaported in vacuo to a gum which was purified by flash column chromatography on silica (15% ethyl acetate/hexane) to give the product contaminated with unreacted 3-nitro-6-trifluoromethyl-2-pyridinone.
  • Step D 3-Benzylsulfonylamino-6-trifluoromethyl-1-allyl-2- pyridinone
  • Step E 3-Benzylsulfonylamino-6-trifluoromethyl-2-pyridinone-1- methylenecarboxaldehyde
  • Step F 3-Benzylsulfonylamino-6-trifluoromethyl-1 - methylenecarboxy-2-pyridinone
  • Step A 3-Benzylsulfonylamino-6-methyl-1 -(4-methylenecarboxamidomethylpiperidinyl)-2-pyridinone
  • Step C 3-Benzylsulfonylamino-6-methyl-1 -[4-methylenecarboxamidomethyl-1-(hydroxyamino)iminomethylpiperidinyl]-2- pyridinone
  • Step A (+/-)-3-( ⁇ -Methylbenzylsulfonylamino)-6-methyl-1- (t-butyl-methylenecarboxy)-2-pyridinone
  • Step B (+/-)-3-( ⁇ -Methylbenzylsulfonylamino)-6-methyl-1-(2- amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)- 2-pyridinone
  • Step B 2-t-Butoxycarbonylamino-5-aminomethyl-6-ethylpyridine
  • Step D 3-Benzylsulfonylamino-6-methyl-1-(2-amino-6-ethyl-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Step A 2-Cyclohexylethylamino-6-methyl-1-(2-t- butoxycarbonylamino-6-methyl-5- methylenecarboxamidomethylpyridinyl )-2-pyridinone
  • Step B 2-Cyclohexylethylamino-6-methyl-1-(2-amino-6-methyl-5- methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Step A ⁇ -N,N-Dimethylaminoethenylcyclopropyl ketone
  • Step D 3-Amino-6-cyclopropyl-1-(t-butyl-methylenecarboxy)-2- pyridinone
  • Step E 3-Benzylsulfonylamino-6-cyclopropyl-1-(t-butyl- methylenecarboxy)-2-pyridinone
  • Benzyl chloroformate (1.8 ml, 12.6 mmol) was added to a solution of 3-amino-6-propyl-2-(1H)-pyridinone (1.63 g, 10.8 mmol) in a mixture of dioxane (25 ml) and 1N NaOH at 0°C. Within minutes a white precipitate formed. The reaction mixture was stirred at the same temperature for 1 hr then at room temperature for an additional hour. The reaction mixture was diluted with water and extracted with ethyl acetate then methylene chloride. Each extract was washed with brine then combined and dried over magnesium sulfate.
  • Step D 3-Amino-6-propyl-1-(t-butyl-methylenecarboxy)-2- pyridinone
  • Step E 3-Benzylsulfonylamino-6-propyl-1-(t-butyl-methylenecarboxy)-2-pyridinone
  • Step F 3-Benzylsulfonylamino-6-propyl-1-methylenecarboxy-2- pyridinone
  • Step A 3-Benzyloxycarbonylmethylamino-6-methyl-1-(t-butyI- methylenecarboxy)-2-pyridinone
  • Step B 3-Benzyloxycarbonylmethylamino-6-methyl-1-methylenecarboxy-2-pyridinone
  • Step C 3-Benzyloxycarbonylmethylamino-6-methyl-1-(2-amino-6- methyl-5-methylenecarboxamidomethyl-pyridinyl)-2- pyridinone :
  • Step A 3-(Ethyl L-phenylalanyl)-6-methyl-1-(t-butyl-methylenecarboxy)-2-pyridinone
  • Step B 3-(Ethyl L-phenylalanyl)-6-methyl-1 -methylenecarboxy-2- pyridinone
  • Step A 3-(4-Chlorobenzyl)sulfonylamino-6-cyclopropyl-1-(2-t- butoxycarbonylamino-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone
  • Step A 3 -Cyclohexylethylsulfonylamino-6-methyl-1-(2-t-butoxycarbonylamino-5-methylenecarboxamidomethylpyridinyl)- 2-pyridinone
  • Step A 3- Vinylsulfonylamino-6-methyl-1-(t-butyl- methylenecarboxy)-2-pyridinone
  • Step B 3-[2-(4-Morpholmoemyl)sulfonylamino]-6-methyl-1-(t- butyl-methylene-carboxy) -2-pyridinone
  • Trypsin assays also contained 1 mM CaCl 2 - In assays wherein rates of hydrolysis of a p-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used was used to measure (at 405 nm) the time dependent appearance ofp- nitroaniline.
  • p-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of 8270 cm- 1 M -1 .
  • Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration ⁇ 0.1 K m into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V o ) or presence of inhibitor (V i ) were measured.
  • V o /V i 1 + [I]/K i (1)
  • compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized vessels.
  • Compounds of Examples 1-4 inhibit human thrombin with Ki values less than 100 nM and inhibit human trypsin with Ki values greater than 500 nM.
  • Treatment infusions were initiated 120 min before the placement of a 3 mm square piece of Whatman No. 1 filter paper saturated with 35% FeCl 3 onto the exposed carotid artery distal to the flow probe. Treatment infusions were continued for an additional 60 minutes after the application of FeCl 3 (total infusion duration 180 minutes) if thrombotic occlusions did not occur, or were terminated 30 minutes after thrombotic occlusion of the vessel. Time to occlusion was defined as the time from application of FeCl 3 to
  • All of the active compound, cellulose, and a portion of the com starch are mixed and granulated to 10% com starch paste.
  • the resulting granulation is sieved, dried and blended with the remainder of the com starch and the magnesium stearate.
  • the resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.
  • An intravenous dosage form of the above-indicated active compound is prepared as follows:
  • the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des composés de formule (I) et notamment de formule (a) inhibiteurs de la thrombine et des occlusions thrombotiques associées.
PCT/US1996/010778 1995-06-27 1996-06-24 Inhibiteurs de la thrombine a base de pyridinone WO1997001338A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63917/96A AU703744B2 (en) 1995-06-27 1996-06-24 Pyridinone-thrombin inhibitors
EP96923399A EP0835109A4 (fr) 1995-06-27 1996-06-24 Inhibiteurs de la thrombine a base de pyridinone
JP9504499A JPH11508558A (ja) 1995-06-27 1996-06-24 ピリジノン トロンビン阻害剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56095P 1995-06-27 1995-06-27
US60/000,560 1995-06-27
US381895P 1995-09-15 1995-09-15
US60/003,818 1995-09-15
GB9603450.9 1996-02-19
GBGB9603450.9A GB9603450D0 (en) 1996-02-19 1996-02-19 Pyridinone thrombin inhibitors

Publications (1)

Publication Number Publication Date
WO1997001338A1 true WO1997001338A1 (fr) 1997-01-16

Family

ID=27268133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010778 WO1997001338A1 (fr) 1995-06-27 1996-06-24 Inhibiteurs de la thrombine a base de pyridinone

Country Status (5)

Country Link
EP (1) EP0835109A4 (fr)
JP (1) JPH11508558A (fr)
AU (1) AU703744B2 (fr)
CA (1) CA2224437A1 (fr)
WO (1) WO1997001338A1 (fr)

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5869487A (en) * 1996-10-24 1999-02-09 Merck & Co., Inc. Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
US5872138A (en) * 1996-09-13 1999-02-16 Merck & Co., Inc. Thrombin inhibitors
WO1999026926A1 (fr) * 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines et alcoxyguanidines et leur utilisation en tant qu'inhibiteurs de protease
US5932606A (en) * 1997-03-24 1999-08-03 Merck & Co., Inc. Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors
WO1999064446A1 (fr) * 1998-06-11 1999-12-16 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de protease a base de pyrazinone
US6011038A (en) * 1997-09-05 2000-01-04 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6017934A (en) * 1997-01-22 2000-01-25 Merck & Co., Inc. Thrombin inhibitors
EP0971891A4 (fr) * 1997-01-22 2000-04-19 Merck & Co Inc Inhibiteurs de thrombine
FR2786482A1 (fr) * 1998-11-27 2000-06-02 Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
US6093717A (en) * 1998-05-26 2000-07-25 Merck & Co., Inc. Imidazopyridine thrombin inhibitors
US6117888A (en) * 1998-09-28 2000-09-12 Merck & Co., Inc. Thrombin inhibitors
US6133297A (en) * 1997-09-30 2000-10-17 Merck & Co., Inc. Thrombin inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
US6147078A (en) * 1998-05-19 2000-11-14 Merck & Co., Inc. Pyrazinone thrombin inhibitors
WO2000069826A1 (fr) * 1999-05-19 2000-11-23 Pharmacia Corporation Pyridones aryle et heteroaryle polycycliques substituees utilisees pour l'inhibition selective de la cascade de coagulation
WO2000069834A1 (fr) * 1999-05-19 2000-11-23 Pharmacia Corporation Pyrazinones d'heteroaryle et d'aryle polycyclique substituees utiles a l'inhibition selective de la coagulation en cascade
WO2000073302A1 (fr) * 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles comme inhibiteurs de protease
WO2000075134A1 (fr) * 1999-06-04 2000-12-14 Merck & Co., Inc. Inhibiteurs de thrombine a base de pyrazinone
US6180627B1 (en) 1998-08-14 2001-01-30 Pfizer Inc. Antithrombotic agents
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
EP0969840A4 (fr) * 1997-03-24 2001-02-28 Merck & Co Inc Inhibiteurs de thrombine
US6204268B1 (en) 1997-04-14 2001-03-20 Cor Therapeutics, Inc Selective factor Xa inhibitors
WO2001019795A1 (fr) * 1999-09-13 2001-03-22 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de serine protease azacycloalcanone
US6211183B1 (en) 1997-04-14 2001-04-03 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
EP1039907A4 (fr) * 1997-12-01 2001-09-19 Merck & Co Inc Inhibiteurs de thrombine
WO2001079261A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
WO2001079262A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Inhibiteurs de la thrombine a base de derives de pyrazinone et pyridinone
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
EP0934064A4 (fr) * 1996-10-24 2002-01-09 Merck & Co Inc Inhibiteurs de thrombine
EP1017393A4 (fr) * 1997-09-05 2002-01-23 Merck & Co Inc Inhibiteurs de thrombine a base de pyrazinone
US6350745B1 (en) 1999-06-04 2002-02-26 Merck & Co., Inc. Thrombin inhibitors
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
WO2001077079A3 (fr) * 2000-04-05 2002-04-11 Pharmacia Corp Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation
US6376499B1 (en) 1998-10-30 2002-04-23 Merck & Co., Inc. Thrombin inhibitors
US6387911B1 (en) 1999-11-23 2002-05-14 Merck & Co., Inc. Pyrazinone thrombin inhibitors
WO2001079195A3 (fr) * 2000-04-14 2002-05-16 Corvas Int Inc Nouveaux inhibiteurs de thrombine de type non covalent
WO2002028825A3 (fr) * 2000-10-06 2002-06-13 Dimensional Pharm Inc Phenylacetamides a substitution aminopyridinyle, aminoguanidinyle et alcoxyguanidinyle utilises comme inhibiteurs de proteases
US6420397B1 (en) 1999-07-09 2002-07-16 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6476016B2 (en) 2000-07-17 2002-11-05 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
US6525076B1 (en) 1996-10-11 2003-02-25 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6534510B2 (en) 2000-03-23 2003-03-18 Merck & Co., Inc. Thrombin inhibitors
WO2003048155A1 (fr) * 2001-12-04 2003-06-12 University Of Ljubljana Inhibiteurs de thrombine
WO2002042272A3 (fr) * 2000-11-20 2003-07-24 Pharmacia Corp Aryl-et-heteroaryl-pyridines polycycliques substituees utiles dans l'inhibition selective de la cascade de la coagulation
US6610692B1 (en) 1998-10-30 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US6635637B2 (en) 2000-08-04 2003-10-21 Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
CN1125051C (zh) * 1997-11-26 2003-10-22 三维药物公司 杂环氨基胍和烷氧基胍及其作为蛋白酶抑制剂的用途
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6777431B2 (en) * 2001-07-13 2004-08-17 Corvas International, Inc. Non-convalent thrombin inhibitors
WO2004091613A3 (fr) * 2003-04-10 2005-01-27 Dimensional Pharm Inc Acetamides a substitution phenyle et leur utilisation en tant qu'inhibiteurs de protease
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
EP1586565A1 (fr) * 1999-05-19 2005-10-19 Pharmacia Corporation Pyrazinones d'hétéroaryle et d'aryle polycyclique substituées utiles à l'inhibition selective de la coagulation en cascade
US6962905B1 (en) 1999-04-21 2005-11-08 Astrazeneca Ab Pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
WO2006135323A1 (fr) * 2005-06-17 2006-12-21 Astrazeneca Ab Derives de 2-oxo-1,2,5,6-tetrahydropyridine inhibiteurs de thrombines
EP1055683A4 (fr) * 1998-02-17 2007-07-25 Nippon Kayaku Kk Nouveau derive d'acetamide et son utilisation
WO2009006217A1 (fr) * 2007-06-29 2009-01-08 Dow Agrosciences Llc 4-chloro-4-alcoxy-1,1,1-trifluoro-2-butanones, leur préparation et leur utilisation pour la préparation de 4-alcoxy-1,1,1-trifluoro-3-buten-2-ones
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509769A2 (fr) * 1991-04-18 1992-10-21 Zeneca Limited Amides hétérocycliques ayant une activité inhibante de HLE
US5405854A (en) * 1992-03-06 1995-04-11 Hoffmann-La Roche Inc. Sulfonamidocarboxamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492895A (en) * 1992-02-14 1996-02-20 Corvas International, Inc. Inhibitors of thrombosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509769A2 (fr) * 1991-04-18 1992-10-21 Zeneca Limited Amides hétérocycliques ayant une activité inhibante de HLE
US5405854A (en) * 1992-03-06 1995-04-11 Hoffmann-La Roche Inc. Sulfonamidocarboxamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., 1994, Vol. 37, BERNSTEIN et al., "Nonpeptidic Inhibitors of Human Leukocyte Elastase. 3.1 Design, Synthesis, X-Ray Crystallographic Analysis, and Structure-Activity Relationships for a Series of Orally Active 3-Amino-6-Phenylpyridin-2-One Trifluoromethyl Ketones", pages 3313-3326. *
See also references of EP0835109A4 *

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872138A (en) * 1996-09-13 1999-02-16 Merck & Co., Inc. Thrombin inhibitors
US6525076B1 (en) 1996-10-11 2003-02-25 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US5869487A (en) * 1996-10-24 1999-02-09 Merck & Co., Inc. Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
EP0934064A4 (fr) * 1996-10-24 2002-01-09 Merck & Co Inc Inhibiteurs de thrombine
US6017934A (en) * 1997-01-22 2000-01-25 Merck & Co., Inc. Thrombin inhibitors
EP0971891A4 (fr) * 1997-01-22 2000-04-19 Merck & Co Inc Inhibiteurs de thrombine
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5932606A (en) * 1997-03-24 1999-08-03 Merck & Co., Inc. Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors
EP0969840A4 (fr) * 1997-03-24 2001-02-28 Merck & Co Inc Inhibiteurs de thrombine
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6204268B1 (en) 1997-04-14 2001-03-20 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6211183B1 (en) 1997-04-14 2001-04-03 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
EP1017393A4 (fr) * 1997-09-05 2002-01-23 Merck & Co Inc Inhibiteurs de thrombine a base de pyrazinone
US6011038A (en) * 1997-09-05 2000-01-04 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
US6133297A (en) * 1997-09-30 2000-10-17 Merck & Co., Inc. Thrombin inhibitors
CN1125051C (zh) * 1997-11-26 2003-10-22 三维药物公司 杂环氨基胍和烷氧基胍及其作为蛋白酶抑制剂的用途
US6566379B1 (en) 1997-11-26 2003-05-20 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6472399B2 (en) 1997-11-26 2002-10-29 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
WO1999026926A1 (fr) * 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines et alcoxyguanidines et leur utilisation en tant qu'inhibiteurs de protease
US6037356A (en) * 1997-11-26 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US7029654B2 (en) 1997-11-26 2006-04-18 Ortho-Mcneil Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6350764B2 (en) 1997-11-26 2002-02-26 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US7402586B2 (en) 1997-11-26 2008-07-22 Ortho-Mcneil Pharmaceutical, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6706021B2 (en) 1997-11-26 2004-03-16 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6245763B1 (en) 1997-11-26 2001-06-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
EP1039907A4 (fr) * 1997-12-01 2001-09-19 Merck & Co Inc Inhibiteurs de thrombine
EP1055683A4 (fr) * 1998-02-17 2007-07-25 Nippon Kayaku Kk Nouveau derive d'acetamide et son utilisation
US6147078A (en) * 1998-05-19 2000-11-14 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6093717A (en) * 1998-05-26 2000-07-25 Merck & Co., Inc. Imidazopyridine thrombin inhibitors
EP1082324A4 (fr) * 1998-05-26 2002-01-02 Merck & Co Inc Composes d'imidazopyridine inhibiteurs de la thrombine
WO1999064446A1 (fr) * 1998-06-11 1999-12-16 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de protease a base de pyrazinone
US6204263B1 (en) 1998-06-11 2001-03-20 3-Dimensional Pharmaceuticals, Inc. Pyrazinone protease inhibitors
US6514978B2 (en) 1998-06-11 2003-02-04 3-Dimensional Pharmaceuticals, Inc. Thromboresistant materials incorporating pyrazinone protease inhibitors
EP1589029A3 (fr) * 1998-06-11 2006-01-18 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Inhibiteurs de protéase à base de pyrazine
US6180627B1 (en) 1998-08-14 2001-01-30 Pfizer Inc. Antithrombotic agents
US6117888A (en) * 1998-09-28 2000-09-12 Merck & Co., Inc. Thrombin inhibitors
US6610692B1 (en) 1998-10-30 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US6376499B1 (en) 1998-10-30 2002-04-23 Merck & Co., Inc. Thrombin inhibitors
FR2786482A1 (fr) * 1998-11-27 2000-06-02 Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique
WO2000032574A1 (fr) * 1998-11-27 2000-06-08 Sanofi-Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique
US6962905B1 (en) 1999-04-21 2005-11-08 Astrazeneca Ab Pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EA005367B1 (ru) * 1999-05-19 2005-02-24 Фармация Корпорейшн Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения
EP1586565A1 (fr) * 1999-05-19 2005-10-19 Pharmacia Corporation Pyrazinones d'hétéroaryle et d'aryle polycyclique substituées utiles à l'inhibition selective de la coagulation en cascade
US6870056B1 (en) 1999-05-19 2005-03-22 Pharmacia Corporation Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
WO2000069834A1 (fr) * 1999-05-19 2000-11-23 Pharmacia Corporation Pyrazinones d'heteroaryle et d'aryle polycyclique substituees utiles a l'inhibition selective de la coagulation en cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
WO2000069826A1 (fr) * 1999-05-19 2000-11-23 Pharmacia Corporation Pyridones aryle et heteroaryle polycycliques substituees utilisees pour l'inhibition selective de la cascade de coagulation
US6326492B1 (en) 1999-05-27 2001-12-04 3-Dimensional Pharmaceuticals, Inc. Heterocyclic protease inhibitors
WO2000073302A1 (fr) * 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles comme inhibiteurs de protease
US6455532B1 (en) 1999-06-04 2002-09-24 Merck & Co., Inc. Pyrazinone thrombin inhibitors
JP2010150275A (ja) * 1999-06-04 2010-07-08 Merck Sharp & Dohme Corp ピラジノントロンビン阻害剤
WO2000075134A1 (fr) * 1999-06-04 2000-12-14 Merck & Co., Inc. Inhibiteurs de thrombine a base de pyrazinone
US6350745B1 (en) 1999-06-04 2002-02-26 Merck & Co., Inc. Thrombin inhibitors
US6420397B1 (en) 1999-07-09 2002-07-16 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
US6469029B1 (en) 1999-09-13 2002-10-22 3-Dimensional Pharmaceuticals, Inc. Azacycloalkanone serine protease inhibitors
US6962942B2 (en) 1999-09-13 2005-11-08 3-Dimensional Pharmaceuticals, Inc. Azacycloalkanone serine protease inhibitors
WO2001019795A1 (fr) * 1999-09-13 2001-03-22 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de serine protease azacycloalcanone
US6387911B1 (en) 1999-11-23 2002-05-14 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6534510B2 (en) 2000-03-23 2003-03-18 Merck & Co., Inc. Thrombin inhibitors
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
WO2001077079A3 (fr) * 2000-04-05 2002-04-11 Pharmacia Corp Pyridones polycycliques 4-aryl et heteroaryl substituees utiles pour l'inhibition selective de la cascade de coagulation
US6916847B2 (en) 2000-04-05 2005-07-12 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6506754B1 (en) 2000-04-14 2003-01-14 Corvas International, Inc. Non-covalent thrombin inhibitors
WO2001079195A3 (fr) * 2000-04-14 2002-05-16 Corvas Int Inc Nouveaux inhibiteurs de thrombine de type non covalent
WO2001079261A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
WO2001079262A1 (fr) * 2000-04-14 2001-10-25 Corvas International, Inc. Inhibiteurs de la thrombine a base de derives de pyrazinone et pyridinone
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US7030110B2 (en) 2000-07-17 2006-04-18 Ortho-Mcneil Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
US6476016B2 (en) 2000-07-17 2002-11-05 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
US6635637B2 (en) 2000-08-04 2003-10-21 Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
WO2002028825A3 (fr) * 2000-10-06 2002-06-13 Dimensional Pharm Inc Phenylacetamides a substitution aminopyridinyle, aminoguanidinyle et alcoxyguanidinyle utilises comme inhibiteurs de proteases
CN1315803C (zh) * 2000-10-06 2007-05-16 三维药物公司 作为蛋白酶抑制剂的氨基吡啶基－,氨基胍基－和烷氧基胍基－取代苯基乙酰胺
US6900231B2 (en) 2000-10-06 2005-05-31 3-Dimensional Pharmaceuticals, Inc. Aminopyridyl-substituted phenyl acetamides as protease inhibitors
US6521663B2 (en) 2000-10-06 2003-02-18 3-Dimensional Pharmaceuticals, Inc. Aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors
WO2002042272A3 (fr) * 2000-11-20 2003-07-24 Pharmacia Corp Aryl-et-heteroaryl-pyridines polycycliques substituees utiles dans l'inhibition selective de la cascade de la coagulation
US6828338B2 (en) 2000-11-20 2004-12-07 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US6777431B2 (en) * 2001-07-13 2004-08-17 Corvas International, Inc. Non-convalent thrombin inhibitors
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7524871B2 (en) 2001-12-04 2009-04-28 University Of Ljubljana, Faculty Of Pharmacy Thrombin inhibitors
WO2003048155A1 (fr) * 2001-12-04 2003-06-12 University Of Ljubljana Inhibiteurs de thrombine
WO2004091613A3 (fr) * 2003-04-10 2005-01-27 Dimensional Pharm Inc Acetamides a substitution phenyle et leur utilisation en tant qu'inhibiteurs de protease
US7550474B2 (en) 2003-04-10 2009-06-23 Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. Substituted phenyl acetamides and their use as protease inhibitors
EP2253612A1 (fr) 2005-04-14 2010-11-24 Novartis AG Composés organiques
WO2006135323A1 (fr) * 2005-06-17 2006-12-21 Astrazeneca Ab Derives de 2-oxo-1,2,5,6-tetrahydropyridine inhibiteurs de thrombines
WO2009006217A1 (fr) * 2007-06-29 2009-01-08 Dow Agrosciences Llc 4-chloro-4-alcoxy-1,1,1-trifluoro-2-butanones, leur préparation et leur utilisation pour la préparation de 4-alcoxy-1,1,1-trifluoro-3-buten-2-ones
CN103382150A (zh) * 2007-06-29 2013-11-06 陶氏益农公司 4-氯-4-烷氧基-1,1,1-三氟-2-丁酮的制备和用途

Also Published As

Publication number Publication date
EP0835109A1 (fr) 1998-04-15
JPH11508558A (ja) 1999-07-27
AU6391796A (en) 1997-01-30
EP0835109A4 (fr) 1999-02-03
CA2224437A1 (fr) 1997-01-16
AU703744B2 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
US5668289A (en) Pyridinone thrombin inhibitors
WO1997001338A1 (fr) Inhibiteurs de la thrombine a base de pyridinone
AU720616B2 (en) Pyridinone thrombin inhibitors
US5792779A (en) Pyridinone thrombin inhibitors
EP0772590B1 (fr) Inhibiteurs de la thrombine
EP0820287B1 (fr) Inhibiteurs de la thrombine
EP0934064B1 (fr) Inhibiteurs de thrombine
US5869487A (en) Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
AU5961398A (en) Thrombin inhibitors
US6117888A (en) Thrombin inhibitors
EP0858262B1 (fr) Inhibiteurs de thrombine
US5798377A (en) Thrombin inhibitors
US5932606A (en) Pyrazinone, pyridinone, piperidine and pyrrolidine thrombin inhibitors
US6017934A (en) Thrombin inhibitors
EP0949921B1 (fr) Inhibiteurs de la thrombine
US6004976A (en) Thrombin inhibitors
WO1999027930A1 (fr) Inhibiteurs de thrombine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1996923399

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2224437

Country of ref document: CA

Ref country code: CA

Ref document number: 2224437

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 504499

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996923399

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996923399

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载